Replies to post #30471 on Savvy Trades and Investments

[SSKILLZ1]

LCI

Yep, so basically forget the numbers, so whatever analyst/institutional firm says is correct 100% of the time, because they put in more time. If you want to buy that, fine. I certainly will not.

Granted IBT on and adjusted level was almost 27% of net income last quarter, so a small hit to margins will bankrupt the company, and totally ignores the pipeline of new drugs. They hardly have the debt levels of say a vrx. and net tangible assets have improved almost 67 million over the last four quarters, Balance sheet health will continue to improve, but I get the dire circumstances the company is in considering all the drugs they have been getting improved and numbers that state otherwise, but everyone is allowed to have an opinion, mine are based in facts of numbers, time will tell if that is right. Also the company is guiding for significant GAAP profitability, stocks like VRX never seem to have. I feel confident in LCI, we will see if I'm right soon enough. All is just my opinion, and I could always be wrong though.

[researcher59]

LCI -1.23 to 19.07 - Citron is obviously biased with a large short position. Six Wall Street analysts also cover the stock and have a mean price target of $30. Maybe there'll be some downgrades coming, but that remains to be seen.